Merck Cancidas Phase IV Studies Of Higher Doses To Conclude In 2005
This article was originally published in Pharmaceutical Approvals Monthly
Merck has agreed to evaluate Cancidas doses above the approved 50 mg daily dose in three studies as part of its Phase IV commitments for the antifungal.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class